4 Analysts Have This to Say About Taysha Gene Therapies
Portfolio Pulse from Benzinga Insights
Taysha Gene Therapies (NASDAQ:TSHA) received 4 analyst ratings in the last quarter, with 3 being bullish and 1 somewhat bullish. The average 12-month price target is $5.75, with a high of $7.00 and a low of $5.00. This target has decreased by 9.16% from the previous average of $6.33. Analysts use various methods to rate stocks, typically updating their ratings quarterly or after major company events.
November 15, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Taysha Gene Therapies has a predominantly bullish outlook from analysts with an average price target of $5.75, which is a decrease from the previous target of $6.33.
The decrease in the average price target suggests a slight negative adjustment in expectations, but the overall bullish sentiment may counterbalance this in the short term. The impact is neutral as the positive ratings could maintain investor confidence despite the lowered target.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100